Trials / Withdrawn
WithdrawnNCT00211354
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Manhattan Eye, Ear & Throat Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina. Complications of retinal vein occlusion which threaten vision include neovascularization(growth of new blood vessels)and macular edema ( accumulation of fluid "leaking" from abnormal blood vessels). Currently, the treatment of retinal vein occlusion is laser photocoagulation. This treatment has found to have limited use in this type of condition.Anecortave Acetate is being considered as an attempt to control the growth of the abnormal blood vessels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate | ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months. |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2007-03-01
- Completion
- 2007-04-01
- First posted
- 2005-09-21
- Last updated
- 2009-02-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00211354. Inclusion in this directory is not an endorsement.